Inhaled version of remdesivir tipped for COVID-19 treatment

Gilead is moving to make out-of-hospital products after the antiviral was shown to be moderately effective as an infusion

An inhaled version of remdesivir is being developed after trials run by its maker showed moderate effectiveness for the drug given by infusion in patients with COVID-19.